• Explore /
  • Poster
  • / Patient-reported outcomes (PROs) in KEYLYNK-010: Pembrolizumab (pembro) plus olaparib (ola) vs abiraterone acetate (abi) or enzalutamide (enza) for patients (pts) with previously treated metastatic castration-resistant prostate cancer (mCRPC).

Patient-reported outcomes (PROs) in KEYLYNK-010: Pembrolizumab (pembro) plus olaparib (ola) vs abiraterone acetate (abi) or enzalutamide (enza) for patients (pts) with previously treated metastatic castration-resistant prostate cancer (mCRPC).

Abstract Poster

Authors

Niven Mehra

Niven Mehra

Radboud University Medical Center, Nijmegen, Netherlands

Niven Mehra , Emmanuel S. Antonarakis , Se Hoon Park , Jeffrey C. Goh , Raymond S. McDermott , Nuria Sala González , Peter C.C. Fong , Richard Greil , Maria De Santis , Patricio Eduardo Yanez , Yi-Hsiu Huang , Stephen Begbie , Felipe Rey , Gero Kramer , Hiroyoshi Suzuki , Todd L. Saretsky , Sameer R. Ghate , Yi Cui , Jeri Kim , Evan Y. Yu

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2023 ASCO Genitourinary Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session A: Prostate Cancer

Track

Prostate Cancer - Advanced,Prostate Cancer - Localized

Sub Track

Symptoms, Toxicities, Patient-Reported Outcomes, and Whole-Person Care

Clinical Trial Registration Number

NCT03834519

Citation

J Clin Oncol 41, 2023 (suppl 6; abstr 131)

DOI

10.1200/JCO.2023.41.6_suppl.131

Abstract #

131

Poster Bd #

D15

Abstract Disclosures

Similar Posters

First Author: Evan Y. Yu

First Author: Ethan M. Basch

First Author: Neeraj Agarwal

First Author: Srikala S. Sridhar